PT2528621T - Antigénios de tuberculose modificados - Google Patents

Antigénios de tuberculose modificados

Info

Publication number
PT2528621T
PT2528621T PT117008599T PT11700859T PT2528621T PT 2528621 T PT2528621 T PT 2528621T PT 117008599 T PT117008599 T PT 117008599T PT 11700859 T PT11700859 T PT 11700859T PT 2528621 T PT2528621 T PT 2528621T
Authority
PT
Portugal
Prior art keywords
modified
tuberculosis antigens
tuberculosis
antigens
modified tuberculosis
Prior art date
Application number
PT117008599T
Other languages
English (en)
Inventor
Blais Normand
Brown James
Gelinas Anne-Marie
Mettens Pascal
Murphy Dennis
Original Assignee
Glaxosmithkline Biologicals Sa
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa, Glaxo Group Ltd filed Critical Glaxosmithkline Biologicals Sa
Publication of PT2528621T publication Critical patent/PT2528621T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT117008599T 2010-01-27 2011-01-27 Antigénios de tuberculose modificados PT2528621T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29871010P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
PT2528621T true PT2528621T (pt) 2016-12-20

Family

ID=44318698

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117008599T PT2528621T (pt) 2010-01-27 2011-01-27 Antigénios de tuberculose modificados

Country Status (24)

Country Link
US (2) US8932600B2 (pt)
EP (1) EP2528621B1 (pt)
JP (2) JP6010463B2 (pt)
KR (1) KR20120129927A (pt)
CN (1) CN102869372B (pt)
AU (1) AU2011209399B2 (pt)
BR (1) BR112012018669A2 (pt)
CA (1) CA2786969C (pt)
CO (1) CO6650338A2 (pt)
CY (1) CY1119518T1 (pt)
DK (1) DK2528621T3 (pt)
EA (1) EA201290590A1 (pt)
ES (1) ES2614266T3 (pt)
HR (1) HRP20161608T1 (pt)
HU (1) HUE031184T2 (pt)
LT (1) LT2528621T (pt)
MX (1) MX2012008790A (pt)
MY (1) MY156697A (pt)
PL (1) PL2528621T3 (pt)
PT (1) PT2528621T (pt)
SG (1) SG182573A1 (pt)
SI (1) SI2528621T1 (pt)
UA (1) UA110103C2 (pt)
WO (1) WO2011092253A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE039159T2 (hu) 2008-07-25 2018-12-28 Glaxosmithkline Biologicals Sa Tuberkulózis Rv2386c protein, ezt tartalmazó készítmények és ezek alkalmazása
WO2010010177A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A. Novel compositions and methods
LT2315597T (lt) 2008-07-25 2018-02-12 Glaxosmithkline Biologicals S.A. Naujos kompozicijos ir būdai
DK2528621T3 (da) * 2010-01-27 2017-01-02 Glaxosmithkline Biologicals Sa Modificerede tuberkuloseantigener
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013123579A1 (en) * 2012-02-24 2013-08-29 Mcmaster University Adenovirus-based tuberculosis vaccine and its use
CN103467582A (zh) * 2012-06-08 2013-12-25 同济大学 结核杆菌重要抗原的高通量筛选及其在结核病诊断中的应用
CN105431166B (zh) * 2013-06-25 2020-09-18 国际艾滋病疫苗行动组织公司 结核病组合物和其使用方法
WO2015148960A1 (en) * 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN105675863B (zh) * 2016-02-17 2017-10-20 遵义医学院附属医院 一组耐多药结核病诊断标志物及其用途
AU2017285424B2 (en) 2016-06-16 2022-08-18 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201618432D0 (en) 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
JP7136777B2 (ja) 2016-12-07 2022-09-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規プロセス
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
IE20190085A3 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
CN109966170B (zh) * 2018-02-13 2022-04-15 深圳高尚科美生物科技有限公司 包含生物大分子的柔性脂质体化妆品及其制备方法
CA3142300A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
WO2022032184A1 (en) * 2020-08-05 2022-02-10 The Administrators Of The Tulane Educational Fund Method of detecting tb in bodily fluid samples

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1786412A (en) * 1929-11-20 1930-12-23 American Telephone & Telegraph Shielding arrangement
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
WO1991012325A1 (en) * 1990-02-09 1991-08-22 E.I. Du Pont De Nemours And Company Htlv envelope antigenic segment
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU666326B2 (en) 1991-08-15 1996-02-08 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Osp A proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
EP0641192B1 (en) 1992-05-18 1997-07-23 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
ATE180407T1 (de) 1993-01-11 1999-06-15 Dana Farber Cancer Inst Inc Induktion der antworten zytotoxischer t- lymphozyten
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5551622A (en) 1994-07-13 1996-09-03 Yoon; Inbae Surgical stapler
AT402926B (de) 1994-12-05 1997-09-25 Hafslund Nycomed Pharma Heterocyclische amide, verfahren zu ihrer herstellung und verwendung
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
WO1996038591A1 (en) 1995-06-02 1996-12-05 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
ES2378051T3 (es) 1995-09-01 2012-04-04 Corixa Corporation Compuestos y métodos para el diagnóstico de la tubercolosis.
IL123506A (en) 1995-09-01 2004-12-15 Corixa Corp Polypeptide compounds and preparations for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
TR199901569T2 (xx) 1996-10-11 2000-12-21 Corixa Corporation T�berk�lozun te�hisi i�in bile�ikler ve y�ntemler.
US6350456B1 (en) 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6627198B2 (en) 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6544522B1 (en) 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
SI1584685T1 (sl) 1998-02-05 2011-07-29 Glaxosmithkline Biolog Sa S tumorjem povezani antigenski derivati iz MAGE druĹľine, uporabljeni za pripravo fuzijskih proteinov s T-pomoĹľnimi epitopi in sestavki za vakcinacijo
AU753995B2 (en) 1998-04-07 2002-10-31 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
ATE442866T1 (de) * 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
EP1401866A2 (en) 2001-02-22 2004-03-31 Institut Pasteur Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20030175294A1 (en) * 2001-03-13 2003-09-18 Corixa Corporation Heterologous fusion protein constructs comprising a Leishmania antigen
EP1475402B1 (en) 2002-02-14 2009-06-24 Mitsui Chemicals, Inc. Polyester resin and catalyst for polyester production, process for producing polyester resin with the catalyst
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
MXPA04012443A (es) * 2002-06-11 2005-04-19 Glaxosmithkline Biolog Sa Composiciones inmunogenicas.
US7205259B2 (en) 2002-07-26 2007-04-17 Kimberly-Clark Worldwide, Inc. Absorbent binder desiccant composition and articles incorporating it
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
JP2008527947A (ja) 2005-01-19 2008-07-24 パンデュイット・コーポレーション 抑制コアを備えた通信チャンネル
US8475803B2 (en) * 2005-04-29 2013-07-02 Fusion Antibodies Limited Assays for diagnosis of tuberculosis and uses thereof
KR20120089475A (ko) 2005-04-29 2012-08-10 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
US9017999B2 (en) 2005-05-03 2015-04-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Importation of mitochondrial protein by an enhanced allotopic approach
JP4468858B2 (ja) 2005-06-01 2010-05-26 オリンパスイメージング株式会社 データ符号化装置、データ符号化方法、プログラム
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7296798B2 (en) 2006-01-31 2007-11-20 Matt Overfield Gameboard, games played on board and methods of play requiring strategy and luck
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
DK2086582T3 (da) 2006-10-12 2013-02-04 Glaxosmithkline Biolog Sa Vaccine omfattende en olie-i-vand-emulsionsadjuvans
EP2368568A1 (en) * 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions and methods for immunodominant antigens
GB0622282D0 (en) * 2006-11-08 2006-12-20 Novartis Ag Quality control methods
PT2137210T (pt) * 2007-03-02 2017-01-09 Glaxosmithkline Biologicals Sa Novos métodos e composições
GB0716070D0 (en) * 2007-08-17 2007-09-26 Fusion Antibodies Ltd Diagnostic method and kit
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
FR2933552B1 (fr) 2008-07-04 2014-10-10 Centre Nat Rech Scient Circuit d'amplification d'un signal representant une variation de resistance d'une resistance variable et capteur correspondant
WO2010010177A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A. Novel compositions and methods
CA2759583C (en) 2009-04-24 2020-06-16 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
WO2011011323A1 (en) 2009-07-21 2011-01-27 Cooper Technologies Company Interfacing a light emitting diode (led) module to a heat sink assembly, a light reflector and electrical circuits
DK2528621T3 (da) * 2010-01-27 2017-01-02 Glaxosmithkline Biologicals Sa Modificerede tuberkuloseantigener
US9119754B2 (en) 2011-10-08 2015-09-01 Michael Dennis Mattress overlay system with positionally adjustable, lateral ramp-wedge bolster structure
US9051890B2 (en) 2013-10-28 2015-06-09 Ford Global Technologies, Llc Method for estimating charge air cooler condensation storage with an intake oxygen sensor
US9903268B2 (en) 2015-04-02 2018-02-27 Ford Global Technologies, Llc Internal combustion engine with two-stage supercharging capability and with exhaust-gas aftertreatment arrangement, and method for operating an internal combustion engine
US9810514B2 (en) 2015-09-08 2017-11-07 Deufol Sunman Inc. Ammunition carrier consumer package

Also Published As

Publication number Publication date
BR112012018669A2 (pt) 2017-09-05
MY156697A (en) 2016-03-15
JP2016166193A (ja) 2016-09-15
AU2011209399B2 (en) 2014-04-10
EP2528621A1 (en) 2012-12-05
KR20120129927A (ko) 2012-11-28
CN102869372A (zh) 2013-01-09
CO6650338A2 (es) 2013-04-15
SG182573A1 (en) 2012-08-30
EP2528621B1 (en) 2016-09-21
DK2528621T3 (da) 2017-01-02
US20150093414A1 (en) 2015-04-02
US20120294882A1 (en) 2012-11-22
EA201290590A1 (ru) 2013-03-29
ES2614266T3 (es) 2017-05-30
CN102869372B (zh) 2016-01-20
HRP20161608T1 (hr) 2017-01-13
US9200044B2 (en) 2015-12-01
SI2528621T1 (sl) 2017-01-31
LT2528621T (lt) 2016-12-12
MX2012008790A (es) 2012-08-17
CA2786969A1 (en) 2011-08-04
CY1119518T1 (el) 2018-03-07
JP6010463B2 (ja) 2016-10-19
JP2013517783A (ja) 2013-05-20
PL2528621T3 (pl) 2017-07-31
CA2786969C (en) 2018-07-24
WO2011092253A1 (en) 2011-08-04
AU2011209399A1 (en) 2012-08-23
HUE031184T2 (en) 2017-06-28
US8932600B2 (en) 2015-01-13
UA110103C2 (uk) 2015-11-25
JP6503309B2 (ja) 2019-04-17

Similar Documents

Publication Publication Date Title
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
HRP20180952T1 (hr) Anti-dll3 antitijelo
PL2528621T3 (pl) Zmodyfikowane antygeny gruźlicy
HK1200853A1 (en) Meditopes and meditope-binding antibodies and uses thereof
IL232399A0 (en) Anti-2fgfr antibodies and their use
ZA201209004B (en) Anti-fgfr2 antibodies
HUE040213T2 (hu) Anti-TIM antitest
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
IL225667A0 (en) A new antigen
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
HK1194388A1 (zh) 抗缺刻蛋白 抗體
PL2603528T3 (pl) Przeciwciała Fab-glikozylowane
GB201020738D0 (en) Antibodies
GB201002238D0 (en) Antibodies
ZA201302459B (en) Antibodies
GB201007957D0 (en) Antibody
GB201017780D0 (en) Antibody
GB201020751D0 (en) Antibodies
GB201005062D0 (en) Antibodies